Larvol Delta - Algok-Bio-Enters-into-Exclusive-Worldwide-License-Agreement-with-BTG-to-Develop-and-Commercialize-Idetrexed-a-ClinicalStage-Folate-ReceptorTargeted-Oncology-Drug

idetrexed (CT900) - Carrick Therap

https://www.biopharmadive.com/press-release/20230410-algok-bio-enters-into-exclusive-worldwide-license-agreement-with-btg-to-dev/

Apr 11, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next